Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 9/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | PREP | P48147 | 2/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3175943 | 0.89 | MEN1 (0.49) | MEN1KMT2ACCR1ACEACE2 | |
| SCHEMBL3172548 | 0.89 | MEN1 (0.51) | MEN1KMT2ACCR1ACEACE2 | |
| SCHEMBL3174391 | 0.86 | KMT2A (0.49) | MEN1KMT2ACCR1ACEACE2 | |
| SCHEMBL12950161 | 0.85 | CCR1 (0.45) | MEN1KMT2ACCR1ACE2ELANE | |
| SCHEMBL12747947 | 0.84 | CASP1 (0.44) | ELANECMA1 | |
| SCHEMBL22798277 | 0.82 | MEN1 (0.53) | MEN1KMT2AACEACE2PREP | |
| SCHEMBL18586359 | 0.82 | MEN1 (0.53) | MEN1KMT2AACEACE2PREP | |
| SCHEMBL20484700 | 0.82 | MEN1 (0.55) | MEN1KMT2AACEACE2 | |
| SCHEMBL18586197 | 0.82 | MEN1 (0.55) | MEN1KMT2AACEACE2 | |
| SCHEMBL3171830 | 0.82 | MEN1 (0.55) | MEN1KMT2ACCR1ACEACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105914-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | US | disclosed |
| US-7652153-B2 | Use in controlling apoptosis, as antiinflammatory agents, in treating autoimmune disease, as antiischemic agents, in treating cardiovascular disorders; for example, (S,S)-3-[2-(3-Acetylamino-2-oxo-2H-pyridin-1-yl)-butyrylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid | VERTEX PHARMACEUTICALS INCORPORATED | 2010-01-26 | — | — | US | disclosed |
| US-20050233979-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105914-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP5, CASP3 | MEN1 2923/4885KMT2A 4138/4885CCR1 2560/4885 |
| US-20050233979-A1 | Caspase inhibitors and uses thereof | CASP1, CASP5, CASP3 | MEN1 2871/4885KMT2A 4063/4885CCR1 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.